Results 261 to 270 of about 38,812 (326)

Evaluation of chemotherapy-induced nausea and vomiting in low, moderate, and highly emetogenic schemes between sexes. [PDF]

Support Care Cancer
Albanell-Fernández M, Rodríguez Mues MC, Figueras C, Altamirano M, Monge-Escartín I, Riu-Viladoms G, Carcelero San Martín E, Corominas Bosch ML, Gaba García L.   +8 more
europepmc   +1 more source

Does Re-importation Reduce Price Differences for Prescription Drugs? Lessons from the European Union. [PDF]

Allsbrook, Jennifer, Kyle, Margaret, Schulman, Kevin   +2 more
core   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The latest consensus on antiemetics

Current Opinion in Oncology, 2018
Purpose of review The present review summarizes and discuss the most recent updated antiemetic consensus. Recent findings Two new neurokinin (NK)1-receptor antagonists, netupitant and rolapitant, have been approved by the Food and Drug Administration and the European Medicines ...
J. Herrstedt
openaire   +5 more sources

Estimating the physicochemical properties of antiemetics using degree-based topological descriptors

Molecular Physics, 2023
Antiemetics are medications that are used to treat or prevent vomiting or nausea. These two common symptoms are the results of different conditions that include procedures, therapies, and medications.
Zhi-hao Hui, M. Naeem, Abdul Rauf, Adnan Aslam   +3 more
semanticscholar   +1 more source

Antiemetics: ASCO Guideline Update.

Journal of Clinical Oncology, 2020
PURPOSE To update the guideline to include new anticancer agents, antiemetics, and antiemetic regimens and to provide recommendations on the use of dexamethasone as a prophylactic antiemetic in patients receiving checkpoint inhibitors (CPIs).
P. Hesketh, M. Kris, E. Basch, Kari Bohlke, S. Barbour, R. Clark-Snow, Michael A. Danso, Kristopher Dennis, Kristopher Dennis, L. Dupuis, S. Dusetzina, C. Eng, P. Feyer, K. Jordan, Kimberly Noonan, Dee Sparacio, G. Lyman   +16 more
semanticscholar   +1 more source

Antiemetics: types, actions and uses.

British journal of hospital medicine, 2020
Nausea and vomiting are common symptoms in the hospital setting, with numerous causes. Common precipitants leading to or complicating inpatient hospital admissions include nausea and vomiting secondary to drugs, gastrointestinal disturbances, metabolic ...
M. Dulay, Jasbir S Dulay
semanticscholar   +1 more source

Antiemetics: American Society of Clinical Oncology Focused Guideline Update.

Journal of oncology practice / American Society of Clinical Oncology, 2016
PURPOSE To update a key recommendation of the American Society of Clinical Oncology antiemetic guideline. This update addresses the use of the oral combination of netupitant (a neurokinin 1 [NK1] receptor antagonist) and palonosetron (a 5 ...
P. Hesketh, Kari Bohlke, M. Kris
semanticscholar   +2 more sources

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.

Journal of Clinical Oncology, 2017
Purpose To update the ASCO guideline for antiemetics in oncology. Methods ASCO convened an Expert Panel and conducted a systematic review of the medical literature for the period of November 2009 to June 2016. Results Forty-one publications were included
P. Hesketh, M. Kris, E. Basch, Kari Bohlke, S. Barbour, Rebecca Anne, Michael A. Danso, K. Dennis, L. Dupuis, S. Dusetzina, C. Eng, P. Feyer, K. Jordan, Kimberly Noonan, Dee Sparacio, Mark R. Somer fi eld, G. Lyman   +16 more
semanticscholar   +1 more source

Economics of antiemetics

Current Opinion in Anaesthesiology, 2002
Numerous studies about postoperative nausea and vomiting management are available and meta-analyses have helped to define the appropriate doses of the effective drugs. Almost all recent papers include some economical considerations. In order to rationalize the therapeutic protocols, strategies including systematic prophylaxis, treatment of established ...
Anne-Marie Diemunsch, Pierre Diemunsch
openaire   +3 more sources

Antiemetic therapy

Critical Reviews in Oncology/Hematology, 2002
The emetogenic potential of cancer chemotherapeutic agents varies according to the agent employed. Among the highly emetogenic agents, cisplatin has been the most studied. As for emesis induced by cisplatin, an optimal antiemetic schedule is effective in 70-90% of cases of acute emesis, in 60% of cases of delayed emesis, whereas acute emesis induced by
L. Licitra, S. Spinazzé, F. Roila
openaire   +3 more sources